Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC and 4D Molecular Therapeutics Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development
Industry Leaders in Gene Therapy Vector Discovery to Create and Develop Products for Treating Severe Ophthalmic Diseases
View HTML
Toggle Summary AGTC Appoints Bruce A. Peacock to Its Board of Directors
Industry Veteran Brings More Than 40 Years of Pharmaceutical and Healthcare Experience to Company
View HTML
Toggle Summary AGTC Files Investigational New Drug Application for the Treatment of X-Linked Retinoschisis
GAINESVILLE, Fla. , March 10, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that it has filed an
View HTML
Toggle Summary AGTC Leadership to Present at Upcoming Scientific and Investor Conferences
GAINESVILLE, Fla. , Feb. 25, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will
View HTML
Toggle Summary AGTC Announces Financial Results for the Second Quarter Ended December 31, 2014
GAINESVILLE, Fla., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the second
View HTML
Toggle Summary AGTC Appoints Stephen W. Potter Chief Business Officer
GAINESVILLE, Fla. , Jan. 29, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced the appointment of Stephen W.
View HTML
Toggle Summary AGTC to Present at Phacilitate Cell & Gene Therapy Forum 2015
GAINESVILLE, Fla. , Jan. 22, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that company management will
View HTML
Toggle Summary AGTC CEO to Present at Piper Jaffray Healthcare Conference on December 3, 2014
GAINESVILLE, Fla., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced that Sue Washer, President and
View HTML
Toggle Summary AGTC Announces Financial Results for the First Quarter Ended September 30, 2014
GAINESVILLE, Fla., Nov. 12, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced financial results for the first
View HTML
Toggle Summary AGTC to Present at Upcoming Conferences
GAINESVILLE, Fla. , Nov. 10, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, announced that company management will be
View HTML
Visionary science for life changing cures.